Focused On-demand Library for Protrudin

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q5T4F4

UPID:

ZFY27_HUMAN

Alternative names:

Spastic paraplegia 33 protein; Zinc finger FYVE domain-containing protein 27

Alternative UPACC:

Q5T4F4; B7Z3S0; B7Z404; B7Z626; G8JLC3; G8JLF0; J3KP98; Q5T4F1; Q5T4F2; Q5T4F3; Q8N1K0; Q8N6D6; Q8NCA0; Q8NDE4; Q96M08

Background:

Protrudin, known as Spastic paraplegia 33 protein and Zinc finger FYVE domain-containing protein 27, plays a pivotal role in RAB11-dependent vesicular trafficking, axonal elongation, and neuronal cell polarity. It is crucial for nerve growth factor-induced neurite formation and ER morphogenesis, balancing sheet-to-tubule transitions and tubule interconnections density.

Therapeutic significance:

Linked to Spastic paraplegia 33, autosomal dominant, Protrudin's involvement in neurodegenerative disorders highlights its potential as a target for therapeutic intervention. Understanding Protrudin's functions could pave the way for novel treatments for spastic paraplegia and related conditions.